Last checked at 
(Alliance News) - Indivior PLC on Tuesday said the US Food & Drug Administration has approved its OPVEE nasal spray for the emergency treatment of opioid overdose.
Indivior is a pharmaceutical company headquartered in the US state of Virginia. It is focused on treatment of addiction.
The company said the treatment has been approved for adults and patients aged 12 years and over, to treat known or suspected opioid overdoses induced by both natural or synthetic opioids.
OPVEE contains nalmefene, an opioid receptor antagonist that provides "fast onset and long duration reversal of opioid-induced respiratory depression". Respiratory depression is the main cause of opioid overdose deaths.
Chief Executive Mark Crossley said: "OPVEE's FDA approval represents a significant achievement in the development of new treatment options to address today's era of opioid overdoses that are driven by powerful synthetic opioids, such as fentanyl.
"OPVEE is an emergency treatment for the fast reversal of respiratory depression triggered by natural or synthetic opioids, including fentanyl, and we are committed to making this novel rescue medication widely available to those who need it most to help save lives."
Indivior shares rose 1.0% to 1,516.00 pence each in London on Tuesday morning.
By Harvey Dorset, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
